CE webinars

This program will define gene therapy, describe gene therapy mechanism of action, goals, and risks of gene therapy. As well as review drug storage and administration requirements.

This program identifies common problems that create challenging patient situations, and problems that can impede discharge. It covers strategies for early interventions, patient selection criteria, and key considerations for important home infusion therapies.

This program will define Parkinson's Disease (PD), describe pathophysiology and epidemiology of  PD, symptoms associated with PD, and wearing "off" periods with disease progression. In addition this program will identify treatment options for PD.

This program provides indications and treatment considerations for some of the key resistant bacteria strains. It also covers standard and contact precautions, and the importance of hand hygiene in controlling the spread of bacteria.

This presentation explains Medicare reimbursement guidelines for patients on home parenteral nutrition therapy, and describes the Medicare documentation requirements for patient qualification and coverage.

The focus of this educational program will be the importance of appropriate patient care in light of the recent opioid “epidemic”.  The program will review some of the psychosocial and political issues involved in the epidemic but will also focus on the need to appropriately assess and provide comprehensive treatment to patients who are experiencing pain.

This program will describe the classification of PAH, pathophysiology and epidemiology of PAH, as well as list the signs and symptoms of PAH and identify treatment options.

This program will describe how personalized medicine is evolving due to advancements in biomarker testing, as well as outline a new therapy, larotrectinib an Neurotrophic Tropomyosin Receptor Kinase (NTRK) inhibitor, as a model for personalized medicine that is changing oncology practice. This program will also discuss and differentiate the five Epithelial Growth Factor Receptor (EGFR) inhibitors used in EGFR positive Non-Small Cell Lung Cancer (NSCLC), explain the dramatic progress in Chronic Lymphocytic Leukemia, and define minimal residual disease (MRD) as a surrogate endpoint of the effectiveness of CLL treatment.

This program provides a review of the therapeutic goals of management for patients with intestinal fistula, and discusses the various etiologies of enterocutaneous fistula. It also outlines the phased nutritional strategies, including enteral and parenteral nutrition support, for intestinal fistula patients.

This program reviews the process regarding Medicare regulations surrounding home inotropic therapy for both inpatient and outpatient sites.